Effect of Sodium-glucose Co-transporter 2 Inhibitor on Ventricular Remodeling

doi:10.12114/j.issn.1007-9572.2020.00.638

Abstract

Abstract: Ventricular remodeling is a pathophysiological process associated with the progression of cardiovascular diseases，the more severe of ventricular remodeling，the worse of prognosis of cardiovascular diseases，and it will eventually lead to heart failure and death.However，there are limited available drugs to delay or reverse ventricular remodeling clinically.As a new type of oral hypoglycemic drug，sodium-glucose co-transporter 2（SGLT-2）inhibitor has been indicated a protective effect on cardiovascular system by many studies.This paper selectively analyzed the effect of SGLT-2 inhibitor on ventricular remodeling in acute myocardial infarction，diabetic cardiomyopathy，hypertensive heart disease and heart failure，so as to provide a reference for more scientific and reasonable application of SGLT-2 inhibitor.

Key words: Ventricular remodeling, Sodium-glucose transporter 2, Myocardial infarction, Diabetic cardiomyopathies, Hypertension, Heart failure

摘要： 心室重构是多种心血管疾病进展过程中伴随的病理生理反应，心室重构越严重则心血管疾病患者预后越差，并最终导致心力衰竭及死亡，但目前临床可用于延缓或逆转心室重构的药物有限。钠-葡萄糖共转运蛋白2（SGLT-2）抑制剂是一种新型口服降糖药，已有多项研究表明其具有心血管保护作用。本文重点分析了SGLT-2抑制剂对急性心肌梗死、糖尿病性心肌病、高血压心脏病及心力衰竭等疾病进展过程中心室重构的影响，以期为临床医师更科学、合理地应用SGLT-2抑制剂提供参考。

关键词: 心室重构, 钠-葡萄糖转运体2, 心肌梗死, 糖尿病心肌病, 高血压, 心力衰竭

LI Zhao,CHENG Gong. Effect of Sodium-glucose Co-transporter 2 Inhibitor on Ventricular Remodeling　[J]. Chinese General Practice, 2021, 24(3): 267-271. DOI: 10.12114/j.issn.1007-9572.2020.00.638.
李兆,程功. 钠-葡萄糖共转运蛋白2抑制剂对心室重构的影响[J]. 中国全科医学, 2021, 24(3): 267-271. DOI: 10.12114/j.issn.1007-9572.2020.00.638.

References

［1］YANG W，ZHANG F，TANG H，et al．Summed thickening score by myocardial perfusion imaging：a risk factor of left ventricular remodeling in patients with myocardial infarction［J］．J Nucl Cardiol，2018，25（3）：742-753．DOI：10.1007/s12350-018-1200-4.
［2］LI X，JIN F，JING C，et al．Predictive value of left ventricular remodeling by area strain based on three-dimensional wall-motion tracking after PCI in patients with recent NSTEMI［J］．Ultrasound Med Biol，2012，38（9）：1491-1501．DOI：10.1016/j.ultrasmedbio.2012.05.006.
［3］BERSELL K，ARAB S，HARING B，et al．Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury［J］．Cell，2009，138（2）：257-270．DOI：10.1016/j.cell.2009.04.060.
［4］BOSTR?M P，MANN N，WU J，et al．C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling［J］．Cell，2010，143（7）：1072-1083．DOI：10.1016/j.cell.2010.11.036.
［5］TAKEDA N，MANABE L，UCHINO Y，et al．Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload［J］．J Clin Invest，2010，120（1）：254-265．DOI：10.1172/JCI40295.
［6］HEINEKE J，AUGER-MESSIER M，XU J，et al．Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart［J］．J Clin Invest，2007，117（11）：3198-3210.
［7］KOSIBOROD M，GAUSE-NILSSON I，XU J，et al．Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure［J］．J Diabetes Complications，2017，31（7）：1215-1221．DOI：10.1016/j.jdiacomp.2017.02.001.
［8］AKKOYUN D C，AKYüZ A，ALPSOY S，et al．Plasma urotensin Ⅱ and neurokinin B levels in acute myocardial infarction and stable coronary artery disease［J］．Anatol J Cardiol，2014，15（8）：628-633．DOI：10.5152/akd.2014.5596.
［9］仲伟智.急性心肌梗死合并糖尿病患者冠状动脉介入治疗后心室重构的变化［J］．中国医药指南，2020，18（18）：108-109.　
ZHONG W Z.Changes of ventricular remodeling after coronary intervention in patients with acute myocardial infarction and diabetes mellitus［J］．Guide of China Medicine，2020，18（18）：108-109.
［10］ULVENSTAM A，HENRIKSSON R，S?DERSTR?M L，et al．Ischemic stroke rates decrease with increased ticagrelor use after acute myocardial infarction in patients treated with percutaneous coronary intervention［J］．Eur J Prev Cardiol，2018，25（11）：1219-1230．DOI：10.1177/2047487318784082.
［11］BHATT D L，FOX K，HARRINGTON R A，et al．Rationale，design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients intervention study［J］．Clin Cardiol，2019，42（5）：498-505．DOI：10.1002/clc.23164.
［12］IANNANTUONI F，DE MARA?ON A M，DIAZ-MORALES N，et al．The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes［J］．J Clin Med，2019，8（11）：1814．DOI：10.3390/jcm8111814.
［13］HEERSPINK H，PERCO P，MULDER S，et al．Canagliflozin reduces inflammation and fibrosis biomarkers：a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease［J］．Diabetologia，2019，62（7）：1154-1166．DOI：10.1007/s00125-019-4859-4.
［14］LENG W，WU M，PAN H，et al．The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus［J］．Ann Transl Med，2019，7（18）：429．DOI：10.21037/atm.2019.09.03.
［15］LEE T M，CHANG N C，LIN S Z，et al．Dapagliflozin，a selective SGLT2 inhibitor，attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts［J］．Free Radic Biol Med，2017，104：298-310．DOI：10.1016/j.freeradbiomed.2017.01.035.
［16］ANVERSA P，OLIVETTI G，CAPASSO J M.Cellular basis of ventricular remodeling after myocardial infarction［J］．Am J Cardiol，1991，68（14）：7D-16D．DOI：10.1016/0002-9149（91）90256-k.
［17］KANG S，VERMA S，HASSANABAD A，et al．Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts：novel translational clues to explain EMPA-REG OUTCOME results［J］．Can J Cardiol，2020，36（4）：543-553．DOI：10.1016/j.cjca.2019.08.033.
［18］SANTOS-GALLEGO C G，REQUENA-IBANEZ J A，ANTONIO R S，et al．Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics［J］．J Am Coll Cardiol，2019，73（15）：1931-1944．DOI：10.1016/j.jacc.2019.01.056.
［19］VERMA S，GARG A，YAN A T，et al．Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes：an important clue to the EMPA-REG OUTCOME Trial？［J］．Diabetes Care，2016，39（12）：e212-213．DOI：10.2337/dc16-1312.
［20］RUBLER S，DLUGASH J，YUCEOGLU Y Z，et al．New type of cardiomyopathy associated with diabetic glomerulosclerosis［J］．Am J Cardiol，1972，30（6）：595-602．DOI：10.1016/0002-9149（72）90595-4.
［21］SOLIMAN E，BYINGTON R P，BIGGER J T，et al．Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus：action to control cardiovascular risk in diabetes blood pressure trial［J］．Hypertension，2015，66（6）：1123-1129.
［22］TAEGTMEYER H，MCNULTY P，YOUNG M E J C.Adaptation and maladaptation of the heart in diabetes：PartⅠgeneral concepts［J］．Circulation，2002，105（14）：1727-1733．DOI：10.1161/01.cir.0000012466.50373.e8.
［23］JOUBERT M，JAGU B，MONTAIGNE D，et al．The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse Model［J］．Diabetes，2017，66（4）：1030-1040．DOI：10.2337/db16-0733.
［24］YE Y，BAJAJ M，YANG H，et al．SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes.Further augmentation of the effects with saxagliptin，a DPP4 inhibitor［J］．Cardiovasc Drugs Ther，2017，31（2）：119-132．DOI：10.1007/s10557-017-6725-2.
［25］LI C，ZHANG J，XUE M，et al．SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart［J］．Cardiovasc Diabetol，2019，18（1）：15．DOI：10.1186/s12933-019-0816-2.
［26］CAO X，BROUGHTON S T，WAITS G S，et al．Interrelations between hypertension and electrocardiographic left ventricular hypertrophy and their associations with cardiovascular mortality［J］．Am J Cardiol，2019，123（2）：274-283．DOI：10.1016/j.amjcard.2018.10.006.
［27］DAWSON A，MORRIS A D，STRUTHERS A D.The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus［J］．Diabetologia，2005，48（10）：1971-1979．DOI：10.1007/s00125-005-1896-y.
［28］COOPER R S，SIMMONS B E，CASTANER A，et al．Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed［J］．Am J Cardiol，1990，65（7）：441-445．DOI：10.1016/0002-9149（90）90807-d.
［29］LIAO Y，COOPER R S，MCGEE D L，et al．The relative effects of left ventricular hypertrophy，coronary artery disease，and ventricular dysfunction on survival among black adults［J］．JAMA，1995，273（20）：1592-1597.
［30］ARTHAM S M，LAVIE C J，MILANI R V，et al．Clinical impact of left ventricular hypertrophy and implications for regression［J］．Prog Cardiovasc Dis，2009，52（2）：153-167．DOI：10.1016/j.pcad.2009.05.002.
［31］DRAZNER M H，RAME J E，MARINO E K，et al．Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years：the Cardiovascular Health Study［J］．J Am Coll Cardiol，2004，43（12）：2207-2215．DOI：10.1016/j.jacc.2003.11.064.
［32］FERRANNINI E，BALDI S，FRASCERRA S，et al．Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes［J］．Diabetes Care，2017，40（6）：771-776．DOI：10.2337/dc16-2724.
［33］LEE H C，SHIOU Y L，JHUO S J，et al．The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats［J］．Cardiovasc Diabetol，2019，18（1）：45．DOI：10.1186/s12933-019-0849-6.
［34］ZHANG N，FENG B，MA X，et al．Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction［J］．Cardiovasc Diabetol，2019，18（1）：107．DOI：10.1186/s12933-019-0914-1.
［35］MCMURRAY J J V，SOLOMON S D，INZUCCHI S，et al．Dapagliflozin in patients with heart failure and reduced ejection fraction［J］．N Engl J Med，2019，381（21）：1995-2008．DOI：10.1056/NEJMoa1911303.
［36］MAGGIONI A P，DAHLSTR?M U，FILIPPATOS G，et al．EURObservational Research Programme：regional differences and 1-year follow-up results of the Heart Failure Pilot Survey（ESC-HF Pilot）［J］．Eur J Heart Fail，2013，15（7）：808-817．DOI：10.1093/eurjhf/hft050.
［37］梁逸强，潘朝锌，何新兵，等．心室重构发病机制的研究进展［J］．河北医药，2013，35（24）：3781-3784.
［38］BYRNE N J，PARAJULI N，LEVASSEUR J，et al．Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure［J］．JACC Basic Transl Sci，2017，2（4）：347-354．DOI：10.1016/j.jacbts.2017.07.003.
［39］SINGH J S S，MORDI I R，VICKNESON K，et al．Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure：the REFORM trial［J］．Diabetes Care，2020，43（6）：1356-1359.
［40］SINGH J S S，FATHI A，VICKNESON K，et al．Research into the effect of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus（REFORM）trial rationale and design［J］．Cardiovasc Diabetol，2016，15：97．DOI：10.1186/s12933-016-0419-0.

[1]	WU Wenjun, WEI Jingjing, LI Xue, REN Hongjie, YU Rui, PENG Guangcao, ZHU Mingjun. Regularity of Prescriptions for Coronary Heart Disease with Hypertension Based on Latent Structure and Association Rules [J]. Chinese General Practice, 2025, 28(30): 3787-3795.
[2]	BAI Jiaxin, CHEN Yu, ZHOU Yiheng, LIU Lidi, YANG Rong, YAO Yi, YUAN Bo, ZHANG Yonggang, LEI Yi, ZENG Rui, JIA Yu, LIAO Xiaoyang. Assessment and Treatment of Early-onset Hypertension: Position Statement of the British and Irish Hypertension Association and Its Implications for Clinical Management of Early-onset Hypertension in China [J]. Chinese General Practice, 2025, 28(30): 3741-3746.
[3]	QIN Bangguo, SUN Jin, LI Man, QIU Jiaojiao, CHENG Bokai, ZHU Ping, WANG Shuxia. Relationship between Non-high-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol Ratio and Left Ventricular Hypertrophy in a Community-based Hypertensive Population [J]. Chinese General Practice, 2025, 28(30): 3753-3760.
[4]	MA Shuangshuang, XING Yanjiang, ZHANG Jiawei, WANG Jing. Research Progress on Cardiac Energy Metabolic Changes in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2025, 28(30): 3831-3840.
[5]	JIA Gaopeng, CHEN Qiuyu. Construction and Validation of a Risk Prediction Model for Recurrent Angina after Percutaneous Coronary Intervention in Elderly Patients with Acute ST-segment Elevation Myocardial Infarction: Based on CYP2C19-related Genetic Testing [J]. Chinese General Practice, 2025, 28(30): 3779-3786.
[6]	LIU Zhenyu, WEI Yunpeng, WANG Jiangmin, XING Yan. Causal Association Study between Sleep Duration and Heart Failure [J]. Chinese General Practice, 2025, 28(27): 3441-3446.
[7]	HAN Xiao, LI Qiyu, GE Pu, FAN Siyuan, LIU Diyue, WU Yibo, ZHANG Qingshuang. The Impact of Behavioral Lifestyle on Quality of Life in Hypertensive Patients [J]. Chinese General Practice, 2025, 28(26): 3248-3258.
[8]	LIU Wenjie, SUN Huang, LUO Wei, CHEN Xuan, PENG Yunzhu, LI Ruijie, MA Mier. Wearable Acoustic-electrocardiographic Remote Monitoring Device for Heart Failure [J]. Chinese General Practice, 2025, 28(25): 3104-3109.
[9]	YU Zizi, LIU Duli, LI Ximin, RUAN Chunyi, YIN Xiangyang, CAI Le. Analysis of the Prevalence and Self-management of Hypertension and Its Influencing Factors in Rural [J]. Chinese General Practice, 2025, 28(25): 3137-3143.
[10]	TANG Shangfeng, HUANG Yangzhen, PAN Yangyang, ZHENG Yanxi, XIONG Zhongbao, ZHANG Kangkang, SONG Jia, WEI Yilin, WANG Chunying, DONG Heng, CHEN Manwei, QING Hua. Specification for the Integration of Healthcare and Prevention Services in Hypertension at the Primary Level [J]. Chinese General Practice, 2025, 28(25): 3089-3095.
[11]	YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058.
[12]	HAN Bing, DU Shuzhen, MENG Xiaoxue, ZHANG Lu, CHEN Zixian, TENG Fengling. Plasma Periostin Levels Correlated with Myocardial Fibrosis in Patients with Heart Failure with Different Ejection Fraction [J]. Chinese General Practice, 2025, 28(24): 2979-2984.
[13]	WANG Rupeng, NAN Jing, HU Yiran, YANG Shenghua, JIN Zening. Predictive Value of the Triglyceride-Glucose Body Mass Index for Slow Flow/No-reflow Phenomenon in Patients with Type 2 Diabetes Mellitus and Acute Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention [J]. Chinese General Practice, 2025, 28(24): 2985-2992.
[14]	WEI Yunhong, YANG Li, WANG Yulu, YE Qiufang, DAI Anni, HE Yan. Study on Cardiopulmonary Function During Different Exercise Stages in Patients with Obesity-related Hypertension [J]. Chinese General Practice, 2025, 28(24): 2972-2978.
[15]	HE Jinyu, ZHULIDUZI Jiesisibieke, ZHANG Ning, LIU Min, LIANG Wannian. Research on Blood Pressure Control and Its Determinants Among Hypertensive Patients Under Standardized Management in China: Status, Challenges, and Future Directions [J]. Chinese General Practice, 2025, 28(24): 2968-2971.